HOUSE_OVERSIGHT_024907.jpg
2.17 MB
Extraction Summary
1
People
6
Organizations
2
Locations
2
Events
1
Relationships
3
Quotes
Document Information
Type:
Investment research report / financial analysis
File Size:
2.17 MB
Summary
This document is page 91 of a Cowen Collaborative Insights investment report dated February 25, 2019. It details the clinical trial results and investor analysis for the drug Epidiolex, specifically focusing on its efficacy in treating seizures (Dravet and LGS) with and without the concomitant use of clobazam, and noting that the drug is effective on its own. While part of a document production marked 'HOUSE_OVERSIGHT', the content is strictly pharmaceutical financial analysis and does not mention Jeffrey Epstein directly.
People (1)
| Name | Role | Context |
|---|---|---|
| Michael Cella | Recipient/Employee |
Email address michael.cella@cowen.com listed in the watermark as the intended recipient.
|
Organizations (6)
| Name | Type | Context |
|---|---|---|
| Cowen |
Author of the report (Cowen Collaborative Insights).
|
|
| GW |
Mentioned as the company noting results ('GW noted...') and presenting analysis; likely GW Pharmaceuticals.
|
|
| NEJM |
New England Journal of Medicine, where trial results were published.
|
|
| Massachusetts General Hospital |
Provided abstracts from compassionate use experience.
|
|
| University of Alabama Birmingham |
Provided abstracts from compassionate use experience.
|
|
| House Oversight Committee |
Bates stamp indicates 'HOUSE_OVERSIGHT'.
|
Locations (2)
| Location | Context |
|---|---|
|
Source of compassionate use data.
|
|
|
Source of compassionate use data.
|
Relationships (1)
Email address michael.cella@cowen.com in watermark.
Key Quotes (3)
"Epidiolex appeared to be well tolerated in the trial."Source
HOUSE_OVERSIGHT_024907.jpg
Quote #1
"The analyses from these two institutions also concluded that Epidiolex does not need to be combined with clobazam to be effective."Source
HOUSE_OVERSIGHT_024907.jpg
Quote #2
"We believe that investors had been hoping for a 12-15% placebo-adjusted 50% response rate for patients on Epidiolex without clobazam in order to be satisfied that Epidiolex was active without clobazam, and therefore the results cleared this bar."Source
HOUSE_OVERSIGHT_024907.jpg
Quote #3
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document